VC Firm Foresite Capital Dishes on Biotech Innovation in China, Opportunities in Immunology

Look at recent big pharma asset acquisitions and new biotech company launches, and you might spot a common theme: The drugs at the heart of these deals were originally developed in China. The portfolio of venture capital firm Foresite Capital…